Pivotal Role of Vascular Endothelial Growth Factor Pathway in Tumor Angiogenesis

Overview

Journal Ann Surg Treat Res

Specialty General Surgery

Date 2015 Jul 2

PMID 26131438

Citations 76

Authors

Sang Hun Lee

Dongjun Jeong

Yong-Seok Han

Moo Jun Baek

Affiliations

Soon will be listed here.

Abstract

The shaping of new blood vessels is a significant event in cancer growth and metastasis. Therefore, the molecular system of cancer angiogenesis has garnered considerable interest in cancer research. The vascular endothelial growth factor (VEGF) and VEGF receptor pathway are recognized as the key regulators of the angiogenic process. Activation of the VEGF/VEGF-receptor pathway initiates signaling cascades that promote endothelial cell growth, migration, and differentiation. Recently, VEGF was shown to play a role in the recruitment of bone marrow-derived endothelial progenitor cells to neovascularization sites. The role of VEGF in promoting tumor angiogenesis and the occurrence of human cancers has led to the rational design and development of agents that selectively target this pathway. Moreover, these anti-VEGF/VEGF receptor agents show therapeutic potential by inhibition of angiogenesis and tumor growth in preclinical models. In this review, we summarize the role of the VEGF pathway during tumor angiogenesis.

Citing Articles

Predictive Value of Circulatory Total VEGF-A and VEGF-A Isoforms for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small-Cell Lung Cancer.

Hirakawa T, Yamaguchi K, Funaishi K, Shimoji K, Sakamoto S, Horimasu Y Cancers (Basel). 2025; 17(4).

PMID: 40002167 PMC: 11853576. DOI: 10.3390/cancers17040572.

The prognostic value of vascular endothelial growth factor in endometrial cancer: A protocol for systematic review and meta-analysis.

Qiang B, Kang Y, Yang J, Su H, Wang Z, Zhang C Medicine (Baltimore). 2024; 103(51):e40933.

PMID: 39705481 PMC: 11666208. DOI: 10.1097/MD.0000000000040933.

Tumor-associated macrophages and CD8+ T cells: dual players in the pathogenesis of HBV-related HCC.

Khan M, Mao B, Hu J, Shi M, Wang S, Ur Rehman A Front Immunol. 2024; 15:1472430.

PMID: 39450177 PMC: 11499146. DOI: 10.3389/fimmu.2024.1472430.

Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy.

Li Q, Geng S, Luo H, Wang W, Mo Y, Luo Q Signal Transduct Target Ther. 2024; 9(1):266.

PMID: 39370455 PMC: 11456611. DOI: 10.1038/s41392-024-01953-7.

Regulation of Tumor Microenvironment through YAP/TAZ under Tumor Hypoxia.

Choi S, Kim D Cancers (Basel). 2024; 16(17).

PMID: 39272887 PMC: 11394240. DOI: 10.3390/cancers16173030.

References

Yang W, Klos K, Yang Y, Smith T, Shi D, Yu D . ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer. 2002; 94(11):2855-61. DOI: 10.1002/cncr.10553. View

Maxwell P, Wiesener M, Chang G, Clifford S, Vaux E, Cockman M . The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399(6733):271-5. DOI: 10.1038/20459. View

Peinado H, Olmeda D, Cano A . Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer. 2007; 7(6):415-28. DOI: 10.1038/nrc2131. View

Ebos J, Lee C, Cruz-Munoz W, Bjarnason G, Christensen J, Kerbel R . Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009; 15(3):232-9. PMC: 4540346. DOI: 10.1016/j.ccr.2009.01.021. View

Glasspool R, Teodoridis J, Brown R . Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer. 2006; 94(8):1087-92. PMC: 2361257. DOI: 10.1038/sj.bjc.6603024. View

Eller J, Longo S, Hicklin D, Canute G . Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery. 2002; 51(4):1005-13; discussion 1013-4. DOI: 10.1097/00006123-200210000-00028. View

Huang J, Soffer S, Kim E, McCrudden K, Huang J, New T . Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res. 2004; 2(1):36-42. View

Maxwell P, Ratcliffe P . Oxygen sensors and angiogenesis. Semin Cell Dev Biol. 2002; 13(1):29-37. DOI: 10.1006/scdb.2001.0287. View

Toomey D, Murphy J, Conlon K . COX-2, VEGF and tumour angiogenesis. Surgeon. 2009; 7(3):174-80. DOI: 10.1016/s1479-666x(09)80042-5. View

10.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

11.

Joo Y, Rew J, Seo Y, Choi S, Kim Y, Park C . Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. J Clin Gastroenterol. 2003; 37(1):28-33. DOI: 10.1097/00004836-200307000-00009. View

12.

Gonzalez-Moreno O, Lecanda J, Green J, Segura V, Catena R, Serrano D . VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop. Exp Cell Res. 2009; 316(4):554-67. DOI: 10.1016/j.yexcr.2009.11.020. View

13.

Bairey O, Boycov O, Kaganovsky E, Zimra Y, Shaklai M, Rabizadeh E . All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells. Leuk Res. 2003; 28(3):243-8. DOI: 10.1016/s0145-2126(03)00256-x. View

14.

Mueller M, Fusenig N . Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004; 4(11):839-49. DOI: 10.1038/nrc1477. View

15.

Kerbel R . Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J Clin Oncol. 2001; 19(18 Suppl):45S-51S. View

16.

Iliopoulos O, Levy A, Jiang C, Kaelin Jr W, Goldberg M . Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A. 1996; 93(20):10595-9. PMC: 38198. DOI: 10.1073/pnas.93.20.10595. View

17.

Eder J, Vande Woude G, Boerner S, LoRusso P . Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 2009; 15(7):2207-14. DOI: 10.1158/1078-0432.CCR-08-1306. View

18.

Pal S, Datta K, Mukhopadhyay D . Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res. 2001; 61(18):6952-7. View

19.

Parikh A, Liu W, Fan F, Stoeltzing O, Reinmuth N, Bruns C . Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma. Cancer. 2003; 98(4):720-9. DOI: 10.1002/cncr.11560. View

20.

Gerber H, Kowalski J, Sherman D, Eberhard D, Ferrara N . Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. 2000; 60(22):6253-8. View